117 related articles for article (PubMed ID: 37300695)
1. Activation-induced cytidine deaminase displays an alternative co-factor for modulating PIM1 expression in diffuse large B cell lymphoma cell lines.
Wang Y; Miao Y; Zhou W; Bi Y; Ji Y; Ma Y
Cell Mol Biol (Noisy-le-grand); 2023 Mar; 69(3):1-7. PubMed ID: 37300695
[TBL] [Abstract][Full Text] [Related]
2. AID and TET2 co-operation modulates FANCA expression by active demethylation in diffuse large B cell lymphoma.
Jiao J; Jin Y; Zheng M; Zhang H; Yuan M; Lv Z; Odhiambo W; Yu X; Zhang P; Li C; Ma Y; Ji Y
Clin Exp Immunol; 2019 Feb; 195(2):190-201. PubMed ID: 30357811
[TBL] [Abstract][Full Text] [Related]
3. AID assists DNMT1 to attenuate BCL6 expression through DNA methylation in diffuse large B-cell lymphoma cell lines.
Jiao J; Lv Z; Zhang P; Wang Y; Yuan M; Yu X; Otieno Odhiambo W; Zheng M; Zhang H; Ma Y; Ji Y
Neoplasia; 2020 Mar; 22(3):142-153. PubMed ID: 32062068
[TBL] [Abstract][Full Text] [Related]
4. Long non-coding RNA SNHG16 promotes proliferation and inhibits apoptosis of diffuse large B-cell lymphoma cells by targeting miR-497-5p/PIM1 axis.
Zhu Q; Li Y; Guo Y; Hu L; Xiao Z; Liu X; Wang J; Xu Q; Tong X
J Cell Mol Med; 2019 Nov; 23(11):7395-7405. PubMed ID: 31483572
[TBL] [Abstract][Full Text] [Related]
5. PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.
Brault L; Menter T; Obermann EC; Knapp S; Thommen S; Schwaller J; Tzankov A
Br J Cancer; 2012 Jul; 107(3):491-500. PubMed ID: 22722314
[TBL] [Abstract][Full Text] [Related]
6. Frequent expression of activation-induced cytidine deaminase in diffuse large B-cell lymphoma tissues from persons living with HIV.
Shponka V; Reveles CY; Alam S; Jaramillo M; Maguire A; Rimsza LM; Kendrick S
AIDS; 2020 Nov; 34(14):2025-2035. PubMed ID: 32773475
[TBL] [Abstract][Full Text] [Related]
7. Expression of activation-induced cytidine deaminase is associated with a poor prognosis of diffuse large B cell lymphoma patients treated with CHOP-based chemotherapy.
Kawamura K; Wada A; Wang JY; Li Q; Ishii A; Tsujimura H; Takagi T; Itami M; Tada Y; Tatsumi K; Shimada H; Hiroshima K; Tagawa M
J Cancer Res Clin Oncol; 2016 Jan; 142(1):27-36. PubMed ID: 26077666
[TBL] [Abstract][Full Text] [Related]
8. Activation-induced cytidine deaminase overexpression in double-hit lymphoma: potential target for novel anticancer therapy.
Zhang J; Shi Y; Zhao M; Hu H; Huang H
Sci Rep; 2020 Aug; 10(1):14164. PubMed ID: 32843697
[TBL] [Abstract][Full Text] [Related]
9. The impact of MYD88 and PIM1 in mature large B-cell non-Hodgkin lymphomas: Defining element of their evolution and prognosis.
Cristian M; Așchie M; Mitroi AF; Deacu M; Boșoteanu M; Bălțătescu GI; Stoica AG; Nicolau AA; Enciu M; Crețu AM; Caloian AD; Orășanu CI; Poinăreanu I
Medicine (Baltimore); 2024 Feb; 103(6):e36269. PubMed ID: 38335426
[TBL] [Abstract][Full Text] [Related]
10. AID is expressed in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas and is not correlated with intraclonal heterogeneity.
Lossos IS; Levy R; Alizadeh AA
Leukemia; 2004 Nov; 18(11):1775-9. PubMed ID: 15385936
[TBL] [Abstract][Full Text] [Related]
11. AID-associated DNA repair pathways regulate malignant transformation in a murine model of BCL6-driven diffuse large B-cell lymphoma.
Gu X; Booth CJ; Liu Z; Strout MP
Blood; 2016 Jan; 127(1):102-12. PubMed ID: 26385350
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of activation-induced cytidine deaminase expression for patients with diffuse large B-cell lymphoma.
Arima H; Fujimoto M; Nishikori M; Kitano T; Kishimoto W; Hishizawa M; Kondo T; Yamashita K; Hirata M; Haga H; Takaori-Kondo A
Leuk Lymphoma; 2018 Sep; 59(9):2085-2095. PubMed ID: 29251015
[TBL] [Abstract][Full Text] [Related]
13. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.
Kreuz S; Holmes KB; Tooze RM; Lefevre PF
Mol Cancer; 2015 Dec; 14():205. PubMed ID: 26643319
[TBL] [Abstract][Full Text] [Related]
14. A promising natural product in diffuse large B-cell lymphoma therapy by targeting PIM1.
Zhang X; Su Q; Zhang Y; Rong R; Chen S; He L; Zhuang W; Li B
Ann Hematol; 2024 Mar; ():. PubMed ID: 38424303
[TBL] [Abstract][Full Text] [Related]
15. A Hyper-IgM Syndrome Mutation in Activation-Induced Cytidine Deaminase Disrupts G-Quadruplex Binding and Genome-wide Chromatin Localization.
Yewdell WT; Kim Y; Chowdhury P; Lau CM; Smolkin RM; Belcheva KT; Fernandez KC; Cols M; Yen WF; Vaidyanathan B; Angeletti D; McDermott AB; Yewdell JW; Sun JC; Chaudhuri J
Immunity; 2020 Nov; 53(5):952-970.e11. PubMed ID: 33098766
[TBL] [Abstract][Full Text] [Related]
16. Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447.
Peters TL; Li L; Tula-Sanchez AA; Pongtornpipat P; Schatz JH
Oncotarget; 2016 Sep; 7(39):63362-63373. PubMed ID: 27556513
[TBL] [Abstract][Full Text] [Related]
17. Activation-induced cytidine deaminase causes recurrent splicing mutations in diffuse large B-cell lymphoma.
Benitez-Cantos MS; Cano C; Cuadros M; Medina PP
Mol Cancer; 2024 Feb; 23(1):42. PubMed ID: 38402205
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
Szydłowski M; Garbicz F; Jabłońska E; Górniak P; Komar D; Pyrzyńska B; Bojarczuk K; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Rymkiewicz G; Cybulska M; Statkiewicz M; Gajewska M; Mikula M; Gołas A; Domagała J; Winiarska M; Graczyk-Jarzynka A; Białopiotrowicz E; Polak A; Barankiewicz J; Puła B; Pawlak M; Nowis D; Golab J; Tomirotti AM; Brzózka K; Pacheco-Blanco M; Kupcova K; Green MR; Havranek O; Chapuy B; Juszczyński P
Cancer Res; 2021 Dec; 81(23):6029-6043. PubMed ID: 34625423
[TBL] [Abstract][Full Text] [Related]
19. MALT lymphoma and extranodal diffuse large B-cell lymphoma are targeted by aberrant somatic hypermutation.
Deutsch AJ; Aigelsreiter A; Staber PB; Beham A; Linkesch W; Guelly C; Brezinschek RI; Fruhwirth M; Emberger W; Buettner M; Beham-Schmid C; Neumeister P
Blood; 2007 Apr; 109(8):3500-4. PubMed ID: 17197434
[TBL] [Abstract][Full Text] [Related]
20. HOXD3 Up-regulating KDM5C Promotes Malignant Progression of Diffuse Large B-Cell Lymphoma by Decreasing p53 Expression.
Cui Y; Lv C; Wen Y; Zhao D; Yang Y; Qiu H; Wang C
Balkan Med J; 2022 Jan; 39(1):30-38. PubMed ID: 34928233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
